Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Defence TherapeuticsDTCFF -9.87%25 Equity-to-Asset is 0.57 as of Mar. 2026. GuruFocus rates DTCFF with a GF Score™ of 25/100. The stock has 1 warning sign investors should review. Among 1,411 Biotechnology companies, Defence Therapeutics ranks worse than 61.52% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Defence Therapeutics Equity-to-Asset Related Terms
Defence Therapeutics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Defence Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DTCFF vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Defence Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Defence Therapeutics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Defence Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Defence Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Defence Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Defence Therapeutics (DTCFF) has a Equity-to-Asset of 0.57 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Defence Therapeutics and its competitors. According to the industry distribution chart, Defence Therapeutics ranks #868 out of 1411 companies in the Biotechnology industry, placing it in the top 61.5%.
Is Defence Therapeutics' Equity-to-Asset too high?
Defence Therapeutics' current Equity-to-Asset is 0.57. The Biotechnology industry median Equity-to-Asset is 0.68. Defence Therapeutics' value of 0.57 is 16.2% below this industry median. Based on the distribution chart, Defence Therapeutics ranks #868 out of 1411 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Defence Therapeutics has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Defence Therapeutics' Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Defence Therapeutics ranks #868 out of 1411 companies for Equity-to-Asset. This places Defence Therapeutics in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Defence Therapeutics' value of 0.57 is 16.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Defence Therapeutics's current Equity-to-Asset of 0.57 is 16.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Defence Therapeutics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Defence Therapeutics's current Equity-to-Asset is 0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Defence Therapeutics stock overvalued right now?
Defence Therapeutics (DTCFF) has a current Equity-to-Asset of 0.57. The current Equity-to-Asset is 0.57 and 16.2% below the Biotechnology industry median of 0.68. Defence Therapeutics' overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Defence Therapeutics (DTCFF), the current Equity-to-Asset is 0.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development. It operates only in Canada.
25GF Score
Get the complete analysis for DTCFF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DTCFF has been successfully added to your 
